



Patient Name: PATIENT, TEST	Sex: F	Date Drawn 03/12/09
Account: TEST CLIENT	Age: 34	Date Tested: 03/12/09
Physician: Physician, Test	DOB: 10/01/1974	Accession: 6333743
Fasting Status: Fasting	Client No: CLIENTACN12345	Patient ID: 3173769

Direct-Measured Cholesterol Panel	Actual	Desirable	Risk		Description
			Low	High	
Total LDL	162	<130 mg/dL	Green	Yellow	LDL ₄₊₃₊₂₊₁ + Lp(a) + IDL
LDL ₄₊₃₊₂₊₁	128	<100 mg/dL	Green	Yellow	Total LDL minus Lp(a) and IDL
Lp(a)	15	<10 mg/dL	Green	Yellow	More atherogenic than LDL
IDL	19	<20 mg/dL	Green	Yellow	More atherogenic than LDL
Total HDL	56	≥40 mg/dL	Green	Yellow	HDL ₂ + HDL ₃
HDL ₂	13	>15 mg/dL	Green	Yellow	Large Buoyant, more protective
HDL ₃	43	>25 mg/dL	Green	Yellow	Small Dense, less protective
Total VLDL	24	<30 mg/dL	Green	Yellow	VLDL ₁₊₂ + VLDL ₃
VLDL ₁₊₂	9.8	<20 mg/dL	Green	Yellow	Buoyant VLDL, less risk
VLDL ₃	15	<10 mg/dL	Green	Yellow	Dense VLDL, more risk
Total Cholesterol	243	<200 mg/dL	Green	Yellow	LDL + HDL + VLDL

Secondary and Emerging Risk Factors	Actual	Desirable	Risk		Description
			Low	High	
Triglycerides	141	<150 mg/dL	Green	Yellow	Linked to increased risk for CHD
Non-HDL Cholesterol	187	<160 mg/dL	Green	Yellow	LDL + VLDL
Remnant Lipoproteins	34	<30 mg/dL	Green	Yellow	IDL + VLDL ₃
Lp(a)	15	<10 mg/dL	Green	Yellow	More atherogenic than LDL
LDL Density (Pattern)	A/B	Pattern A	Green	Yellow	B: more risk; A/B intermediate risk; A: less risk
LDL Subclasses (mg/dL) LDL ₄ =23.7, LDL ₃ =56.6, LDL ₂ =22.3, LDL ₁ =25.4					LDL ₄₊₃ small, dense. LDL ₂₊₁ large, buoyant

Apolipoproteins	Actual	Desirable	Risk		Description
			Low	High	
Apo B	125	<109 mg/dL	Green	Yellow	Sum atherogenic lipoprotein particles
Apo A1	161	>145 mg/dL	Green	Yellow	Sum anti-atherogenic lipoprotein particles
Apo B/A1 ratio	0.78	<0.75	Green	Yellow	Low ratio indicates lower risk

Metabolic Syndrome/Insulin Resistant Assessment		Considerations
Atherogenic Dyslipidemia <input type="checkbox"/> Triglycerides ≥150 mg/dL <input checked="" type="checkbox"/> HDL ₂ <10mg/dL males <15mg/dL females <input type="checkbox"/> Pattern B	Physician Input Required <input type="checkbox"/> Blood Pressure ≥130 / ≥85 mm Hg <input type="checkbox"/> Fasting Glucose ≥100 mg/dL <input type="checkbox"/> Abdominal Obesity ≥102 cm (≥40 in) male ≥88 cm (≥35 in) female	The normal LDL target of <130mg/dL* for moderate risk patients can be lowered to <100mg/dL* due to the presence of any of the following ATP III emerging risks factors: <input type="checkbox"/> LDL Size - Dense (Pattern B) <input checked="" type="checkbox"/> Remnant Lipoproteins elevated <input checked="" type="checkbox"/> Lp(a) * If patient is defined as very high risk LDL target of <70 mg/dL can be considered.

Clinicians: If you have questions about test interpretation and implications for care, call (877) 519-4807 to speak with a Medical Science Consultant.

Patients: If you have had a VAP Test and are interested in nutrition and exercise instructions, call Our Healthy Heart Program at (866) 827-8378.

Note: Atherotech does not mandate or advise treatment for individual patients. Patient treatment and recommendations are the responsibility of the clinician.

Atherotech, Inc.
201 London Parkway
Birmingham, AL 35211

Phone: (877) 901-8510
Fax: (205) 314-7403
Lab Director: Dr. Kris Kulkarni

www.Atherotech.com
© 2011 Atherotech
V-PH1-3.2011